Yükleniyor... / Loading...
This study evaluated the safety and effect of an experimental drug called SRA737, used alone with Gemcitabine or together with Gemcitabine and Cisplatin, in people with advanced solid tumors. It included people with advanced cancer (such as high-grade serous ovarian cancer or small cell lung cancer) that had relapsed or progressed despite standard treatment. It was conducted in Phase 1/Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Key Inclusion Criteria:
1. For Dose Escalation: subjects with locally advanced or metastatic, histologically or cytologically proven solid tumor, relapsed after or progressing despite conventional treatment
2. Life expectancy of at least 12 weeks
3. World Health Organization (WHO) performance status of 0-1
4. Must meet select hematological and biochemical laboratory indices
5. Archival tumor tissue or accessible tumor and willingness to consent to a biopsy
Expansion Only:
1. Histologically or cytologically proven advanced malignancy of the following types, for which no other conventional therapy is considered appropriate:
* High-grade serous ovarian cancer (HGSOC)
* Small cell lung cancer
* Soft tissue sarcoma
* Cervical/anogenital cancer
2. Measurable disease per RECIST v1.1
3. Subjects must have predicted sensitivity to Chk1 inhibition based on factors including: genetic profiling of tumor tissue or ctDNA, HPV status, and germline BRCA1 and BRCA2 gene status. All subjects will have genetic profiling from tumor tissue or ctDNA; profiling will be performed prospectively if required to evaluate Chk1 sensitivity or otherwise performed retrospectively.
1. For subjects with HGSOC, documented somatic or germline BRCA1 and BRCA2 wild-type status will confer eligibility without requirement for prospective genetic profiling. If documented BRCA status is not available, genetic profiling may be performed prospectively to determine eligibility.
2. Subjects with SCLC are eligible without requirement for prospective genetic profiling on the basis of very high prevalence of cancer related alterations in the tumor suppressor genes (eg, TP53 and RB1) in this population.
3. For subjects with STS, and any others for whom genetic profiling is performed prospectively, eligibility will be determined by the sponsor's review of genetic abnormalities detected in genes in the following categories:
Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as RB1, TP53, etc. For relevant cancers, positive human papilloma virus (HPV) status is also considered for eligibility.
* The DNA damage response pathway including ATM, BRCA1, BRCA2, mismatch repair genetic alterations and/or high microsatellite instability.
* Genetic indicators of replicative stress such as gain of function/amplification of Chk1 or ATR or other related gene.
* Oncogenic drivers such as MYC, CCNE1, etc.
4. For subjects with anogenital cancer, known HPV positive status will confer eligibility without requirement for prospective genetic profiling. If HPV status is not known or not positive, genetic profiling (or HPV testing where appropriate) may be performed prospectively to determine eligibility. Subjects with cervical cancer or squamous cell carcinoma of the anus are eligible without requirement for prospective genetic profiling based on the very high prevalence of HPV positivity in these populations.
Key Exclusion Criteria:
1. Received the following prior or current anticancer therapy in the timeframes noted prior to receiving SRA737 and have recovered from toxicity:
1. Radiotherapy, chemotherapy, PARP inhibitors, other targeted therapies, or other IMPs within 2 weeks
2. Nitrosoureas or Mitomycin C within 6 weeks
3. Any prior treatment with a Chk1 inhibitor at any point or prior treatment with an ATR inhibitor within 6 months
2. No more than 3 previous treatment regimens for advanced disease (not applicable to HGSOC expansion cohort)
3. Other malignancy within the past 2 years, except for adequately treated tumors
4. If, in the opinion of the Investigator, the subject is highly likely to experience clinically significant myelosuppression
5. Ongoing toxic manifestations of previous treatments greater than NCI-CTCAE Grade 1
6. History of allergy to gemcitabine
7. New or progressing brain metastases. Subjects with brain metastases that have been asymptomatic and radiologically stable over an 8-week period and have not been treated with steroids during that time may be included with approval from the sponsor.
8. High medical risk because of nonmalignant systemic disease
9. Serologically positive for hepatitis B, hepatitis C or HIV
10. Serious cardiac condition, left ventricular ejection fraction \< 45% at baseline, history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment, unless approved by the sponsor.
11. Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone marrow within the previous 8 weeks
12. Peanut allergy
13. QTcF \> 450 msec in adult makes and \> 470 msec in adult females
14. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of SRA737
15. Inability to swallow capsules without chewing or crushing
16. Is a participant or plans to participate in another interventional clinical trial
17. Any other condition which in the Investigator's opinion would not make the subject a good candidate